Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 7/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17705264 | 0.86 | LMNA (0.48) | BRD4LMNASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL17705221 | 0.86 | BRD4 (0.45) | BRD4LMNASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL18892534 | 0.78 | LMNA (0.45) | BRD4LMNASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL17705260 | 0.77 | BRD4 (0.34) | BRD4LMNASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL17705225 | 0.76 | MEN1 (0.34) | BRD4LMNASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL17705215 | 0.74 | TP53 (0.38) | LMNASMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL17705268 | 0.74 | LMNA (0.33) | BRD4LMNASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL16293910 | 0.73 | LMNA (0.41) | BRD4LMNASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL17700677 | 0.73 | LMNA (0.36) | BRD4LMNASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL17705266 | 0.71 | F7 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9657006-B2 | Macrocyclic factor VIIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160115159-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115159-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | F7, F12, F5 | BRD4 3808/4885LMNA 963/4885SMN1; SMN2 2965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.